natgillin/translations-raw huggingface dataset:
reactions (hypersensitivity), see ’Take special care with Betaferon’), skin breakdown and tissue destruction (necrosis) at injection site (see ‘Take special care with Betaferon’), flu -like symptoms, fever, pain, chest pain, accumulation of fluid in arm, leg or face, lack/loss of strength, chills, sweating, malaise
bolečino, alergijskimi reakcijami (preobčutljivostjo), glejte poglavje Bodite posebej pozorni pri uporabi zdravila Betaferon), razkroj kože in odmrtje tkiva (nekroza) na mestu injiciranja (glejte poglavje Bodite posebej pozorni pri uporabi zdravila Betaferon), gripi podobni simptomi, zvišana telesna temperatura, bolečine, bolečine v prsnem košu, kopičenje tekočine v rokah, nogah ali obrazu, pomanjkanje/ izguba moči, mrzlica, potenje, splošno slabo počutje
Side effects reports on the marketed product (from spontaneous reporting):
neželeni učinki, zabeleženi v obdobju trženja zdravila (spontano poročanje):
► Very common side effects (more than 1 user in 10 are likely to get these):
► zelo pogosti neželeni učinki (verjetno jih bo imel več kot 1 od 10 uporabnikov):
- flu-like symptoms*,
- gripi podobni simptomi *
- chills*,
- mrzlica *
- fever*,
- zvišana telesna temperatura *
- injection site reaction*,
- reakcije na mestu injiciranja *
- injection site inflammation*,
- vnetje na mestu injiciranja *
- injection site pain*.
- bolečina na mestu injiciranja *
(*frequencies based on clinical trials)
(* pogostost temelji na podatkih iz kliničnih preskušanj)
► Common side effects (1 to 10 users in 100 are likely to get these):
► pogosti neželeni učinki (verjetno jih bo imelo 1 do 10 od 100 uporabnikov):
- skin breakdown and tissue destruction (necrosis) at injection site*
- razkroj kože in odmrtje tkiva (nekroza) na mestu injiciranja *
► Uncommon side effects (1 to 10 users in 1,000 are likely to get these):
► občasni neželeni učinki (verjetno jih bo imelo 1 do 10 od 1. 000 uporabnikov):
- the number of white cells and red cells in the blood may fall, the number of platelets
- zmanjša se lahko število belih in rdečih krvnih celic, pa tudi število trombocitov (ki
(which help the blood to clot) may fall,
pomagajo pri strjevanju krvi)
- increase of blood pressure,
- zvišan krvni tlak
- nausea,
- slabost
- vomiting,
- bruhanje
- liver test may change (rises in the blood levels of enzymes the liver produces),
- spremembe jetrnih testov (povečane vrednosti jetrnih encimov v krvi)
- swollen and usually itching patches of skin or mucous membranes (urticaria),
- otekli in običajno srbeči deli kože ali sluznice (urtikarija)
- rash,
- osip
- itching (pruritus),
- srbenje (pruritus)
- loss of scalp hair,
- izpadanje las
- p ainful muscles,
- bolečina v mišicah
- muscle stiffness.
- otrplost mišic
► Rare side effects (1 to 10 users in 10,000 are likely to get these):
► redki neželeni učinki (verjetno jih bo imelo 1 do 10 od 10. 000 uporabnikov):
- swollen lymph glands,
- otekle bezgavke
- serious allergic (hypersensitivity) reactions,
- resne alergijske (preobčutljivostne) reakcije
- the thyroid gland does not work properly (too much or too little hormone is produced),
- nepravilno delovanje ščitnice (proizvaja se premalo ali preveč hormona)
- a certain type of blood fats (triglycerides) may increase, see ‘Take special care with Betaferon’
- povečajo se lahko vrednosti določenih vrst maščob v krvi (trigliceridi), glejte poglavje Bodite
(will show up in blood tests),
posebno pozorni pri uporabi zdravila Betaferon (pokaže se pri krvnih preiskavah)
- severe loss of appetite leading to weight loss (anorexia),
- izguba apetita, ki povzroči zmanjšanje telesne mase (anoreksija)
- confusion,
- zmedenost
- anxiety,
- tesnoba
- mood swings,
- nihanja v razpoloženju
- suicide attempt,
- poskusi samomora
- convulsion,
- konvulzije
- disease of the heart muscle (cardiomyopathy),
- obolenje srčne mišice (kardiomiopatija)
- faster heart beat,
- hitrejši srčni utrip
- irregular, rapid beating or pulsation of the heart (palpitation),
- nepravilno, hitro bitje ali utripanje srca (palpitacije)
- sudden shortness of breath (bronchospasm),
- nenadna kratka sapa (bronhospazem)
- shortness of breath (dyspnea),
- kratka sapa (dispneja)
- pancreatitis, see ‘Take special care with Betaferon’,
- pankreatitis, glejte poglavje Bodite posebno pozorni pri uporabi zdravila Betaferon
- a specific liver enzyme (gamma GT) and a reddish yellow pigment (bilirubin), which is
- poveča se lahko vrednost specifičnega jetrnega encima (gama GT) in rdečkasto rumenega
produced by your liver, may rise (this will show up in blood tests),
pigmenta (bilirubina), ki ga proizvajajo jetra (to pokažejo krvne preiskave)
- hepatitis,
- hepatitis
- skin discoloration,
- sprememba barve kože
- menstrual disorders,
- motnje menstruacije
- chest pain,
- bolečine v prsnem košu
- malaise,
- splošno slabo počutje
- sweating,
- potenje
- loss of weight.
- izguba telesne mase
Do not use after the expiry date which is stated on the pack.
Zdravila Betaferon ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
However, if you are not able to do so, it will be okay for 3 hours, if kept at 2-8 °C (in a refrigerator).
Če to ni mogoče, jo lahko hranite 3 ure na temperaturi 2 do 8 °C (v hladilniku).
What Betaferon contains:
Kaj vsebuje zdravilo Betaferon
The active substance is Interferon beta-1b, 250 microgram per millilitre when reconstituted.
Zdravilna učinkovina je interferon beta- 1b, 250 mikrogramov na mililiter po rekonstituciji.
104 The other ingredients are − in the powder: mannitol and human albumin, − in the solvent (sodium chloride solution 5.4 mg/ml (0.54% (w/v)): sodium chloride, water for injections.
v prašku: manitol in humani albumin, v vehiklu (raztopina natrijevega klorida 5, 4 mg/ ml (0, 54% (m/ v))): natrijev klorid, voda za injekcije.
The Betaferon powder is provided in a 3-millilitre vial, containing 300 microgram (9.6 million IU) Interferon beta-1b per vial.
Prašek zdravila Betaferon je na voljo v 3- mililitrski viali, ki vsebuje 300 mikrogramov (9, 6 milijonov i. e.) interferona beta- 1b na vialo.
After reconstitution each millilitre contains 250 microgram (8 million IU) Interferon beta-1b.
Po rekonstituciji vsebuje vsak mililiter 250 mikrogramov (8 milijonov i. e.) interferona beta- 1b.
The solvent for Betaferon is provided in a 2.25-millilitre pre-filled syringe and contains 1.2 ml sodium chloride solution 5.4 mg/ml (0.54%).
Vehikel za zdravilo Betaferon je na voljo v 2, 25- mililitrski napolnjeni brizgi in vsebuje 1, 2 ml raztopine natrijevega klorida 5, 4 mg/ ml (0, 54%).
What Betaferon looks like and contents of the pack:
Izgled zdravila Betaferon in vsebina pakiranja
− multipacks comprising 5 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or − multipacks comprising 15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or − 3-month packs comprising 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or − 3-month packs comprising 3x14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or − titration pack for the first 12 injections comprising 4 triple packs, each containing 3 vials with powder, 3 pre-filled syringes with solvent, 3 vial adapters with needle, 6 alcohol wipes
praškom, 3 napolnjene injekcijske brizge z vehiklom, 3 adapterje za viale z iglami, 6 alkoholnih blazinic.
Marketing authorisation holder and manufacturer:
Imetnik dovoljenja za promet in izdelovalec:
Bayer Schering Pharma AG, D-13342 Berlin, Germany
Bayer Schering Pharma AG, D- 13342 Berlin, Nemčija
105 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
105 Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
106 Annex:
106 Dodatek:
You will best tolerate Betaferon in the beginning if you start with a low dose and gradually increase to the full standard dose (see first part of this leaflet, section 3. ‘How to use Betaferon’).
Na začetku zdravljenja boste zdravilo Betaferon bolje prenašali, če boste zdravljenje začeli z manjšimi odmerki in jih postopoma povečevali do celotnega odmerka (glejte prvi del navodila, poglavje 3.
The syringes in this titration pack are marked accordingly with the appropriate doses (0.25; 0.5; 0.75 or 1.0 ml).
Brizge v tem setu za titriranje so ustrezno označene z odmerki (0, 25; 0, 5; 0, 75 in 1 ml).
The following instructions and pictures explain how to prepare Betaferon for injection and how to inject Betaferon yourself.
Naslednja navodila in slike pojasnjujejo, kako zdravilo Betaferon pripravite za uporabo in kako si ga sami injicirate.
− Set up a permanent storage area in a convenient location out of the reach of children so your Betaferon and other supplies are always easy to find.
- Izberite stalno, primerno, otrokom nedostopno mesto, kjer boste imeli zdravilo Betaferon in druge
For details on storage conditions see section 5. ‘How to store Betaferon’ in the first part of this leaflet.
Shranjevanje zdravila Betaferon v navodilu za uporabo.
This makes it easier to remember and easier to plan a block of time when you will not be interrupted.
Za nadaljnje podrobnosti o uporabi zdravila Betaferon preberite poglavje 3.
After mixing Betaferon, you should give the injection immediately (if Betaferon is not used immediately, see section 5. ‘How to store Betaferon’ in the first part of this leaflet).
Shranjevanje zdravila Betaferon v prvem delu tega navodila za uporabo).
− Be consistent - use Betaferon as described in section 3. ‘How to use Betaferon’ in the first part of this leaflet.
Kako uporabljati
Always double-check your dosage. − Keep your syringes and syringe disposal unit out of the reach of children; lock the supplies away if possible. − Never re-use syringes or needles. − Always use a sterile (aseptic) technique as described in here. − Always place the used syringes in the proper disposal unit.
- Brizge in posode za odstranjevanje brizg hranite zunaj dosega otrok; če je mogoče, hranite pribor
107 B) Getting ready to inject
107 B) Priprava na injiciranje
The best places for injections are where the skin is loose and soft, and away from joints, nerves, or bones, for example the abdomen, arm, thigh or buttocks..
Najboljše mesto za injiciranje je predel, kjer je koža mlahava in mehka, ne v bližini sklepov, živcev in kosti, na primer trebuh, roka, stegno ali zadnjica.
Follow the sequence described in the schedule at the end of the Annex (see Part II, ‘Rotating injection sites’) and you will come back to your first injection site area after 8 injections (16 days).
Na prvo mesto injiciranja se boste vrnili po 8 injekcijah (16 dneh).
In the Betaferon pack you will find: − 1 Betaferon vial (with powder for solution for injection), − 1 pre-filled syringe of solvent for Betaferon (sodium chloride solution 5.4 mg/ml (0.54%)), − 1 vial adapter with a pre-attached needle, − 2 alcohol swabs to clean the skin and vial.
- 1 napolnjeno injekcijsko brizgo z vehiklom za zdravilo Betaferon (0, 54- odstotna raztopina
If you have a Betaferon titration pack you will find 4 differently coloured and numbered triple packs, each containing: • 3 Betaferon vials (with powder for solution for injection) • 3 pre-filled syringes with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml (0.54%)) • 3 vial adapters with a pre-attached needle • 6 alcohol wipes for skin and vial cleaning In addition you will need a disposal unit for used syringes and needles.
Če imate set za titriranje zdravila Betaferon, boste v njem našli štiri različno obarvana in oštevilčena tridelna pakiranja, ki vsebujejo:
Start with the yellow triple pack 1 containing 3 syringes with a 0.25-ml marking, for treatment days 1, 3 and 5.
Začnite z rumenim tridelnim pakiranjem 1, ki vsebuje 3 brizge z oznako 0, 25 ml za 1., 3. in 5. dan zdravljenja.
Use then the red triple pack 2 containing 3 syringes with a 0.5 -ml marking, for treatment days 7, 9 and 11.
Potem uporabite rdeče tridelno pakiranje 2, ki vsebuje 3 brizge z oznako 0, 5 ml za 7., 9. in 11. dan zdravljenja.
Continue with the green triple pack 3 containing 3 syringes with a 0.75-ml marking, for treatment days 13, 15 and 17.
Nadaljujte z zelenim tridelnim pakiranjem 3, ki vsebuje 3 brizge z oznako 0, 75 ml za 13., 15. in 17. dan zdravljenja.
Use the blue triple pack 4 containing 3 syringes with a 0.25; 0.5; 0.75 and 1.0-ml marking, for treatment days 19, 21 and 23.
Uporabite modro tridelno pakiranje 4, ki vsebuje 3 brizge z oznakami 0, 25, 0, 5, 0, 75 in 1 ml za 19., 21. in 23. dan zdravljenja.
108 C) Reconstituting the solution, step by step
108 C) Rekonstitucija raztopine po korakih
4 – Open the blister pack containing the vial adapter, but leave the vial adapter inside.
4 – Odprite pretisni omot z adapterjem za vialo, vendar ga pustite v omotu.
This is to keep it sterile.
Ne dotikajte se adapterja za vialo, da ostane sterilen.
5 – Before attaching the adapter remove and discard the alcohol wipe and rest the vial on a flat surface.
5 – Pred namestitvijo adapterja odstranite in odvrzite alkoholno blazinico, viala naj bo na ravni površini.
6 - Hold the blister pack on the outside and place it on top of the vial.
6 – Pretisni omot držite na zunanji strani in ga namestite na vrh viale.
109 8 - Pick up the syringe.
109 8 - Vzemite brizgo.
Throw away the tip cap.
Odstranite pokrov z obračanjem in ga zavrzite.
This will form the syringe assembly.
9 - Povežite brizgo z odprtino na stranici adapterja za vialo, tako da vstavite konico brizge, jo potisnete in zasučete v smeri urnega kazalca (glejte puščico) ter tako sestavite sklop brizge.
110 D) Drawing up the injection
110 D) Izvlek količine za injiciranje
0.25 ml for first three injections (at day 1, 3, 5 of therapy), or 0.5 ml for the injections at day 7, 9, 11 of therapy, or 0.75 ml for the injections at day 13, 15, 17 of therapy.
0, 25 ml za prve tri injekcije (1., 3. in 5. dan zdravljenja) ali 0, 5 ml za injekcije na 7., 9, in 11 dan zdravljenja ali 0, 75 ml za injekcije na 13., 15. in 17 dan zdravljenja.
14 - After drawing up the solution turn the syringe assembly so that the needle is pointing up.
14 – Po izvleku raztopine sklop brizge obrnite tako, da je igla obrnjena navzgor.
This allows any air bubbles to rise to the top of the solution.
Tako bodo zračni mehurčki na površju raztopine.
Remove them by gently tapping the syringe and pushing the plunger to the respective marking on the syringe.
Če ste pri titriranju injicirali manj kot 1 ml, zračni mehurčki verjetno niso prisotni, vendar se pri injiciranju celotnega odmerka zračni mehurčki lahko dvignejo Odstranite jih z rahlim potrkavanjem na brizgo in potisnite bat do ustrezne oznake na brizgi.
13) and pull the plunger back a little to withdraw the solution back into the syringe.
Če je v raztopini preveč zračnih mehurčkov, jo vrnite v vodoravni položaj (glejte sliko 13) in povlecite bat malo nazaj in izvlecite raztopino iz viale nazaj v brizgo.
111 17 - Dispose of the vial and any unused portion of the solution in the disposal unit
17 - Vialo in neporabljen del raztopine zavrzite v posodo za odpadke.
18 - You are now ready to inject.
111 18 - Sedaj ste pripravljeni za injiciranje.
If, for some reason, you are not able to inject the Betaferon immediately, you can keep the reconstituted solution in the syringe in a refrigerator for up to 3 hours before using.
Če si zaradi kakršnegakoli razloga zdravila Betaferon ne morete vbrizgniti takoj, lahko rekonstituirano raztopino v brizgi do 3 ure hranite v hladilniku.
3 - Remove the cap from the needle by pulling not twisting it.
Pokrov povlecite, ne upogibajte ga.
Please note:
Pomembno:
Betaferon can also be administered with an auto-injector.
Zdravilo Betaferon lahko dajate tudi z avtoinjektorjem.
112 F) Quick review of the process
112 F) Kratek pregled postopka
- - - - - -
- Adapter za vialo pritrdite na vialo.
Take out the required content for one injection Attach vial adapter to the vial Connect the syringe to the vial adapter Push syringe plunger to transfer all the solvent into the vial Turn the syringe assembly over and draw up the prescribed amount of the solution Remove vial from syringe - you are now ready to inject
- Sklop brizge obrnite navzgor in izvlecite potrebno količino raztopine.
113 PART II:
113 DEL II:
Rotation Schedule:
Načrt izmeničnega injiciranja:
114 ROTATION SCHEDULE:
114 NAČRT MENJAVANJA MEST INJICIRANJA:
AREA 8
PREDEL
AREA 7
PREDEL
115 PART III:
115 PRIMER KARTICE O UPORABI ZDRAVILA:
BETAFERON Medication record
Zapisovanje mest injiciranja in datumov
Instructions for keeping track of your injection sites and dates
10– 15 cm od komolca
- Select an injection site for your first injection.
desna stran trebuha
- Clean the injection site with an alcohol wipe and let it air-dry.
10– 15 cm levo stegno od dimelj desno stegno
- After your injection, fill in the used injection site and date on the table in your injection record
10– 15 cm od kolena sredina noge
(see the example: ‘Keeping track of your injection sites and dates’).
desna stran zadnjice leva stran zadnjice
116 EXAMPLE OF A MEDICATION RECORD:
116 Poseben dodatek:
INTRODUCTORY LEAFLET FOR TITRATION PACK
NAVODILO ZA UPORABO SETA ZA TITRIRANJE
You will best tolerate Betaferon in the beginning if you start with a low dose and gradually increase to the full standard dose (see first part of the package leaflet, section 3. ‘How to use Betaferon’).
Na začetku zdravljenja boste zdravilo Betaferon bolje prenašali, če boste zdravljenje začeli z manjšimi odmerki in jih postopoma povečevali do celotnega odmerka (glejte prvi del navodila, poglavje 3.
The syringes have special markings for this dose.
V setu za titriranje so štiri različno obarvana in oštevilčena tridelna pakiranja, ki vsebujejo:
Please follow in detail the instructions for use below.
- 3 viale zdravila Betaferon (s praškom za raztopino za injiciranje),
Start by using the yellow triple pack which is clearly marked with a “1” on the top right hand side of the box.
- 3 napolnjene injekcijske brizge z vehiklom za prašek Betaferon (raztopina natrijevega klorida
This first triple pack should be used for treatment days 1, 3 and 5.
- 3 adapterje za viale z iglami,
It contains specially marked syringes with 0.25 ml marking.
- 6 alkoholnih blazinic za čiščenje kože in vial.
This will help you to inject the required dose only.
Brizge imajo posebne oznake za odmerke.
After finishing with the yellow pack, start using the red triple pack which is clearly marked with a "2" on the top right hand side of the box.
Vsebuje brizge z oznako 0, 25 ml.
It contains specially marked syringes with 0.50 ml marking.
Vsebuje brizge z oznako 0, 5 ml.
After finishing with the red pack, start using the green triple pack which is clearly marked with a "3" on the top right hand side of the box This third triple pack should be used for treatment days 13, 15 and 17.
To tretje tridelno pakiranje je namenjeno za uporabo 13., 15 in 17. dan zdravljenja.
It contains specially marked syringes with 0.75 ml marking.
Vsebuje brizge z oznako 0, 75 ml.
Finally, after finishing with the green pack, start using the blue triple pack which is clearly marked with a "4" on the top right hand side of the box.
Na koncu, po končani uporabi zelenega tridelnega pakiranja, začnite z uporabo modrega tridelnega pakiranja, ki je jasno označen s številko » 4 « na zgornji strani škatle.
This last triple pack should be used for treatment days 19, 21 and 23.
To zadnje tridelno pakiranje je namenjeno za uporabo 19., 21 in 23. dan zdravljenja.
It contains specially marked syringes with 0.25, 0.5, 0.75 and 1.0 ml markings.
Vsebuje brizge z oznakami 0, 25, 0, 5, 0, 75 in 1 ml.
Use the complete amount of solvent for reconstitution of the Betaferon powder, and inject the full dose 1.0 ml.
Uporabite celotno količino raztopine za rekonstitucijo praška Betaferon in injicirajte celoten odmerek 1 ml.
For a description of how to prepare and use the Betaferon powder, please refer to section 3. ‘How to use Betaferon’in the first part of the package leaflet and to the Annex'Self-injection procedure' in the second part of the package leaflet.
Kako uporabljati zdravilo Betaferon v prvem delu navodila za uporabo in Dodatek, Postopek za samoinjiciranje v drugem delu navodila za uporabo.
118
117
The educational leaflet shall contain the following key elements: • That the use of epoetin alfa products can cause immunogenicity which in rare cases may lead to Pure Red Cell Aplasia (PRCA) • That with other epoetin products, the risk of immunogenicity in Chronic Kidney Disease (CKD) is increased with the subcutaneous (sc) route. • There is insufficient data on Binocrit to know the size of any increased immunogenicity risk with sc use • Therefore, the sc route is not recommended for patients with CKD • The loss of efficacy or other symptoms of the development of immunogenicity should be investigated • Any suspected case of Pure Red Cell Aplasia or development of immunogenicity should be reported to the MAH
Izobraževalna brošura mora vsebovati naslednje ključne elemente: • Uporaba zdravil z epoteinom alfa lahko povzroči imunogenost, ki lahko v redkih primerih povzroči čisto aplastično anemijo (Pure Red Cell Aplasia – PRCA). • Pri drugih zdravilih, ki vsebujejo epotein, je tveganje za pojav imunogenosti pri kronični ledvični bolezni (KLB) povečano pri uporabi subkutane (s. c.) poti odmerjanja. • Podatkov o zdravilu Binocrit je premalo, da bi vedeli, za koliko se poveča tveganje za pojav imunogenosti pri subkutani uporabi zdravila. • Subkutana pot odmerjanja zato ni priporočena za bolnike s KLB. • Treba je raziskati izgubo učinkovitosti ali druge simptome pojava imunogenosti. • Vse primere suma čiste aplastične anemije ali pojava imunogenosti je treba sporočiti imetniku dovoljenja za promet z zdravilom.
Binocrit is a ‘ biosimilar’ medicine.
Zdravilo Binocrit je „ podobno biološko “ zdravilo.
This means that Binocrit is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘ reference medicine’).
To pomeni, da je zdravilo Binocrit podobno biološkemu zdravilu, ki je v Evropski uniji (EU) že odobreno in vsebuje isto zdravilno učinkovino (znano tudi kot „ referenčno zdravilo “).
The reference medicine for Binocrit is Eprex/ Erypo.
Referenčno zdravilo za Binocrit je zdravilo Eprex/ Erypo.
Binocrit is used in the following situations: • to treat anaemia (low red blood cell counts) that is causing symptoms in patients with ‘ chronic renal failure’ (long-term, progressive decrease in the ability of the kidneys to work properly) or other kidney problems; • to treat anaemia in adults receiving chemotherapy for certain types of cancer and to reduce the need for blood transfusions; • to increase the amount of blood that can be taken in adult patients with moderate anaemia who are going to have an operation and donate their own blood before surgery (autologous blood transfusion); • to reduce the need for blood transfusions in adults with mild anaemia who are about to undergo major orthopaedic (bone) surgery, such as hip surgery.
Zdravilo Binocrit se uporablja v naslednji primerih: • za zdravljenje anemije (majhno število rdečih krvnih celic), ki povzroča simptome pri bolnikih s kronično odpovedjo ledvic (dolgotrajno in napredujoče upadanje sposobnosti ledvic za pravilno delovanje) ali drugimi težavami z ledvicami; • za zdravljenje anemije pri odraslih, pri katerih s kemoterapijo zdravijo določene vrste raka, in za zmanjšanje potrebe po transfuziji krvi; • za povečanje količine krvi, ki jo je mogoče odvzeti odraslim bolnikom z zmerno anemijo, ki bodo imeli kirurški poseg in pred operacijo darujejo lastno kri (avtologna transfuzija krvi); • za zmanjšanje potrebe po transfuziji krvi pri odraslih z blago obliko anemije pred zahtevnejšo ortopedsko operacijo (operacijo na kosteh), kakršna je operacija kolkov.